EGFR and cancer: The median IC50 of the NOTCH1 mutant type cancer cell lines was smaller than that of the wild-type, indicating that an EGFR inhibitor (gefitinib) has potential therapeutic effects for T-cell leukemia with a NOTCH1 mutation (Fig. 4a, b).